Quantitative prediction of long-term molecular response in TKI-treated CML – Lessons from an imatinib versus dasatinib comparison

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2045-2322

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Quantitative prediction of long-term molecular response in TKI-treated CML – Lessons from an imatinib versus dasatinib comparison ; volume:8 ; number:1 ; day:17 ; month:8 ; year:2018 ; pages:1-13 ; date:12.2018
Scientific reports ; 8, Heft 1 (17.8.2018), 1-13, 12.2018

Creator: Glauche, Ingmar

Contributor: Kuhn, Matthias
Baldow, Christoph
Schulze, Philipp
Rothe, Tino
Liebscher, Hendrik
Roy, Amit
Wang, Xiaoning
Roeder, Ingo
SpringerLink (Online service)

DOI: 10.1038/s41598-018-29923-4

URN: urn:nbn:de:101:1-2018102714430392557910

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 8:47 AM UTC

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Glauche, Ingmar
Kuhn, Matthias
Baldow, Christoph
Schulze, Philipp
Rothe, Tino
Liebscher, Hendrik
Roy, Amit
Wang, Xiaoning
Roeder, Ingo
SpringerLink (Online service)

Other Objects (12)

The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib

BCAT1 contributes to the development of TKI-resistant CML

Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial)

Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML

New dosing schedules of dasatinib for CML and adverse event management

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib

Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study

Is There a Role for Dose Modification of TKI Therapy in CML?

Is imatinib still the best choice as first-line oral TKI

Graffiti | Streetart

TKi | TKi

Identifizierung und funktionelle Charakterisierung von microRNAs bei Imatinib-Therapieresistenz der CML

Ascites does not accompany pleural effusion developing under dasatinib therapy in patients with CML-CP

The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib

BCAT1 contributes to the development of TKI-resistant CML

Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial)

Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML

New dosing schedules of dasatinib for CML and adverse event management

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib

Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study

Is There a Role for Dose Modification of TKI Therapy in CML?

Is imatinib still the best choice as first-line oral TKI

Graffiti | Streetart

TKi | TKi

Identifizierung und funktionelle Charakterisierung von microRNAs bei Imatinib-Therapieresistenz der CML

Ascites does not accompany pleural effusion developing under dasatinib therapy in patients with CML-CP

The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib

BCAT1 contributes to the development of TKI-resistant CML

Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial)

Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML

New dosing schedules of dasatinib for CML and adverse event management

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib

Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study

Is There a Role for Dose Modification of TKI Therapy in CML?

Is imatinib still the best choice as first-line oral TKI

Graffiti | Streetart

TKi | TKi

Identifizierung und funktionelle Charakterisierung von microRNAs bei Imatinib-Therapieresistenz der CML

Ascites does not accompany pleural effusion developing under dasatinib therapy in patients with CML-CP

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read and agree to the privacy policy for the collection of personal data.*

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Quantitative prediction of long-term molecular response in TKI-treated CML – Lessons from an imatinib versus dasatinib comparison

Show object

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib

BCAT1 contributes to the development of TKI-resistant CML

Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial)

Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML

New dosing schedules of dasatinib for CML and adverse event management

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib

Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study

Is There a Role for Dose Modification of TKI Therapy in CML?

Is imatinib still the best choice as first-line oral TKI

TKi | TKi

Identifizierung und funktionelle Charakterisierung von microRNAs bei Imatinib-Therapieresistenz der CML

Ascites does not accompany pleural effusion developing under dasatinib therapy in patients with CML-CP

The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib

BCAT1 contributes to the development of TKI-resistant CML

Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial)

Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML

New dosing schedules of dasatinib for CML and adverse event management

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib

Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study

Is There a Role for Dose Modification of TKI Therapy in CML?

Is imatinib still the best choice as first-line oral TKI

TKi | TKi

Identifizierung und funktionelle Charakterisierung von microRNAs bei Imatinib-Therapieresistenz der CML

Ascites does not accompany pleural effusion developing under dasatinib therapy in patients with CML-CP

The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib

BCAT1 contributes to the development of TKI-resistant CML

Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial)

Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML

New dosing schedules of dasatinib for CML and adverse event management

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib

Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study

Is There a Role for Dose Modification of TKI Therapy in CML?

Is imatinib still the best choice as first-line oral TKI

TKi | TKi

Identifizierung und funktionelle Charakterisierung von microRNAs bei Imatinib-Therapieresistenz der CML

Ascites does not accompany pleural effusion developing under dasatinib therapy in patients with CML-CP

Related objects

Reset password